Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC
Season 14, Episode 12, Sep 12, 08:42 PM
Share
Subscribe
In this podcast, experts Aditya Bardia, MD, MPH, FASCO; and Erika P. Hamilton, MD, discuss recent efficacy and safety data of TROP2-targeted antibody-drug conjugate (ADC) plus immune checkpoint inhibitor combinations for advanced triple-negative breast cancer (TNBC).